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TORTELLA, F. C., E. ECHEVARRIA, L. ROBLES, H. I. MOSBERG AND J. W. HOLADAY. Anticonvulsant effects 
ofmu (DAGO) and delta (DPDPE) enkephalins in rats. PEPTIDES 9(5) 1177-1181, 1988.--The effects of highly selective mu 
and delta opioid peptide agonists were determined in two rat models of experimentally-induced convulsions, the flurothyl 
threshold test and the maximal electroshock test. lntracerebroventricular injections of the mu selective enkephalin DAGO 
(0.3-2.2 nmol) resulted in a dose-related protection in both seizure models. Pretreatment with a low dose of naloxone (29 
nmol) or the irreversible mu antagonist fl-FNA (21 nmol), but not the delta opioid antagonist ICI 154,129 (50 nmol), 
antagonized the anticonvulsant actions of DAGO. Intracerebroventricular injections of the delta selective enkephalin 
DPDPE (70-140 nmol) also resulted in seizure protection. These effects were selectively antagonized by the delta 
antagonist ICI 174,864 (2.8 nmol), but not by pretreatment with/3-FNA. Thus, using agonists and antagonists highly 
selective for mu and delta opioid receptors, anticonvulsant actions of enkephalin have been described against chemically- 
and electrically-induced convulsions in rats. 
Anticonvulsant effects DAGO DPDPE 
SINCE the initial discovery of an anticonvulsant action of 
opioid peptides in the rat (32) numerous reports have de- 
scribed protective effects of opioid peptides in several animal 
models of experimental epilepsy (28). Moreover,  the anti- 
convulsant properties of  these peptides can be recognized as 
specific for opioid receptors since their actions were antag- 
onized by naloxone or other opioid antagonists (28). 
It has been well established that the pharmacological ac- 
tions of  opioids are not mediated by a homogenous receptor 
population, but instead involve at least four receptor sub- 
types (mu, delta, kappa, and sigma) (14, 20, 46). It is there- 
fore likely that the anticonvulsant actions of opioid peptides 
are also mediated via specific subtypes of opioid receptors.  
For  example, previous studies using selective antagonists for 
mu and delta receptors demonstrated that the increase in 
convulsive threshold in rats produced by the mixed mu- and 
delta-directed opioid etorphine and D-Ala2-D-LeuS-enke - 
phalin (DADLE) were predominantly,  but not exclusively, 
mediated by mu and delta receptors,  respectively (36). More 
recently, anticonvulsant effects have been described for the 
kappa opioid peptide dynorphin (3, 11, 29) and the nonpep- 
tide kappa U50,488 (34,41). Hence, it would appear that mu, 
delta and kappa opioid receptors are all capable of producing 
anticonvulsant activity in the central nervous system (CNS). 
The purpose of the present study was to evaluate more 
thoroughly the role of mu and delta opioid receptors in the 
anticonvulsant actions of enkephalin. For  this purpose, the 
rat flurothyl and maximal electroshock (MES) tests were 
used to study the effects of  the most highly selective 
enkephalin ligands presently available for mu and delta bind- 
ings sites, namely D-AlaZ-N-methyl-Phe4-Gly~-ol-enkephalin 
(DAGO) (12, 17, 18) and D-Pen2-D-PenS-enkephalin 
(DPDPE) (17, 22, 23). 
METHOD 
Male Sprague-Dawley rats (225--275 g) obtained from 
Zivic-Miller Laboratories (Pittsburgh, PA) were anesthetized 
with ketamine HC1 (100 mg/kg, IP) and stereotaxically im- 
planted with an ICV cannula aimed at the right lateral ven- 
tricle. Three to five days postsurgery, the animals were ran- 
domly assigned to control or treatment groups for testing. 
1Preliminary reports of this work were presented at the annual meetings of the American Society of Pharmacology and Experimental 
Therapeutics, Baltimore, MD, 1986 and the Federation of American Societies for Experimental Biology, Washington, DC, 1987. 
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FIG. 1. (A) Anticonvulsant effect of DAGO against flurothyl convulsions. *p<0.05 compared to saline controls (ANOVA, Dunnett's test). (B) 
Effects naloxone, /3-FNA or ICI 154,129 to antagonize the DAGO-induced increase in seizure threshold. *p<0.05 compared to 
corresponding saline group and +p<0.05 compared to DAGO alone (Student's t-test). 
For  seizure threshold studies, rats were individually exposed 
to the volative convulsant flurothyl, and the latency to a 
generalized convulsion with loss of posture was determined 
as previously described (34). MES convulsions were induced 
by transauricular electrical stimulation using a Wahlquist 
shock apparatus (Wahlquist Inst. Co., Salt Lake City, UT). 
Stimulus parameters were 50 mA for 2 sec at 60 Hz, produc- 
ing a suprathreshold generalized convulsion (34). 
Thirty rain prior to testing, separate groups of rats (n=6-  
14 per group) received either a single ICV injection of saline 
(5 or l0/~l  ), DAGO (0.3-2.2 nmol) or DPDPE (70 or 140 
nmol) followed by a 2 ~l saline flush. The animals were then 
subjected to either flurothyl or MES, and the mean seizure 
threshold (ST) to a flurothyl-induced convulsion, or the 
presence or absence of MES-induced tonic hindlimb exten- 
sion (THE), was recorded. 
In separate experiments,  the opioid receptor specificity of  
the response was determined using the nonselective 
antagonist naloxone (29 nmol), the selective irreversible mu 
antagonist/~-funaltrexamine (fl-FNA; 21 nmol) (27), or the 
selective delta antagonists N,N-Bisally-Tyr-Gly-Gly-~0- 
(CH~S)-Phe-Leu-OH (ICI 154,129; 50 nmol) (6,39) and 
N,N-Bisallyl-Tyr-Aib-Aib-Phe-Leu-OH (ICI 174,864; 2.8 
nmol) (25). In these studies, naloxone, ICI 174,864 and IC1 
154,129 were administered ICV 5 rain prior to the agonists; 
f l -FNA was administered ICV 18--20 hr prior to the agonists. 
With the exception of ICI 174-864, all the compounds used in 
the study were dissolved in saline immediately prior to test- 
ing. ICI 174,864 was dissolved in 0.1 M sodium bicarbonate. 
Throughout the study, control groups received the appro- 
priate vehicle injection and, each animal was used only 
once. DPDPE was synthesized by Dr. H. I. Mosberg. DAGO 
was purchased from Peninsula Laboratories,  Inc. (San Car- 
los, CA). Naloxone was a gift of Endo DuPont (Wilmington, 
DE). f l -FNA and ICI 174,864 and 154,129 were gifts from the 
National Institute on Drug Abuse and ICI Pharmaceuticals 
(Macclesfield, UK), respectively. 
R E S U L T S  
Effects of Enkephalin Analogs Against Flurothyl 
Convulsions 
The effects of DAGO or  DPDPE on flurothyl ST are 
shown in Figs. 1A and 3. Baseline STs for the DAGO and 
DPDPE control groups were 340__+12 sec (Fig. 1A) and 
337___7 sec (Fig. 3), respectively. ICV injections of DAGO 
produced a significant, dose-related increase in ST, reaching 
a maximum of  65% above control (559-+38 sec) at the highest 
dose tested (Fig. 1A). The administration of  DPDPE also 
resulted in a significant, dose-dependent increase in the con- 
vulsive threshold to flurothyl. However,  in these rats, ST 
was only increased approximately 15--20% above control 
(389-+ 12 sec) at the highest dose of  DPDPE tested (Fig. 3). It 
is important to note that doses of DPDPE greater than 140 
nmol (98/~g) were not used since preliminary experiments 
revealed that higher doses of  DPDPE (125-150 /~g, ICV) 
caused nonopioid behaviors in rats, characterized by barrel- 
rolling and postural abnormalities. 
Effects of Enkephalin Analogs Against MES Convulsions 
In saline-treated animals, MES produced THE in 80- 
100% of the animals tested (Fig. 2A, B and Fig. 4). ICV 
administered DAGO produced a significant anticonvulsant 
effect against MES convulsions, causing a dose-related 
blockade of THE. At the highest dose tested, only 10% of  the 
animals demonstrated THE (Fig. 2A). A significant blockade 
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FIG. 2. (A) Anticonvulsant effect of DAGO against MES convulsions. *p<0.05 compared to saline controls (ANOVA, Mann-Whiney U-test). 
(B) Effects of naloxone,/3-FNA or IC1 154,129 to antagonize the DAGO-induced blockade of THE. *p<0.05 compared to corresponding 
saline group and +p<0.05 compared to DAGO alone (Mann-Whitney U-test). 
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FIG. 3. Anticonvulsant effect of DPDPE against flurothyl convul- 
sions and antagonism by/3-FNA or ICI 174,864. *.o<0.05 compared 
to saline controls and +p<0.05 compared to DPDPE alone (Stu- 
dent's t-test). 







. - , z , . ,  
Saline ~-FNA 
(21 nmol) 




I C 1 1 7 4  
(2.8 nmoi) 
FIG. 4. Anticonvulsant effect of DPDPE against MES convulsions 
and antagonism by /3-FNA or ICI 174,864. *p<0.05 compared to 
saline controls and +p<0.05 compared to DPDPE alone (Mann- 
Whitney U-test). 
of  seizure spread also occurred following injections of 
DPDPE. Complete blockade of THE was observed in 50% of 
the animals tested (Fig. 4). 
Effects of OpioM Antagonists 
ICV injections of naloxone, /3-FNA, ICI 174,864 or 
ICI 154,129 had no significant effect on flurothyl STs (Figs. 
1B and 3) or MES-induced THE (Figs. 2B and 4). However,  
in both seizure tests, the anticonvulsant effects of 2.2 nmol 
DAGO were significantly antagonized by naloxone or 
/3-FNA. In this regard, the DAGO-induced increase in ST 
was reduced from 559+-38 sec to 432+- 25 sec and 426+_20 sec 
by naloxone (29 nmol) and /3-FNA (21 nmol) pre- 
treatment, respectively (Fig. 1B). Similarly, DAGO-induced 
blockade of THE was completely attenuated by these doses 
of antagonists (Fig. 2B). In contrast, pretreatment with ICI 
154,129 (50 nmol) failed to antagonize the anticonvulsant ef- 
fects of  DAGO in either seizure test (Figs. 1B and 2B). 
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In the flurothyl and MES tests, the anticonvulsant prop- 
erties of  DPDPE were antagonized by ICI 174,864 (2.8 
nmol), but not fl-FNA (21 nmol). Here, pretreatment with 
the delta antagonist returned DPDPE-induced increases in 
flurothyl ST (389± 12 sec) to control levels (342± 11 sec) (Fig. 
3), and completely antagonized the DPDPE-induced block- 
ade of MES-induced THE (Fig. 4). As seen in Figs. 3 and 4, 
fl-FNA failed to antagonize the anticonvulsant effects of 
DPDPE in either seizure test. Naloxone was not tested in 
DPDPE-treated rats. 
DISCUSSION 
Studies of CNS excitability in several animal species and 
experimental models have shown that the seizure protective 
effects of  opioid peptides are due to specific interactions 
with central opioid receptors [see (28) for review]. The pres- 
ent study confirms and further extends these findings by 
demonstrating that enkephalins highly selective for mu and 
delta binding sites are anticonvulsant in the rat. Further- 
more, the selectivity of  their anticonvulsant actions at mu 
and delta receptors was demonstrated using specific opioid 
receptor antagonists. 
The agonist DAGO and the antagonist fl-FNA have been 
previously shown to be selective for mu opioid receptors (12, 
17, 18, 27, 36, 38) while the agonist DPDPE and the 
antagonist compounds ICI 154,129 and ICI 174,864 represent 
the most selective ligands for delta opioid sites (6, 17, 22, 23, 
25, 27, 38). Thus, our results demonstrating that DAGO or 
DPDPE will protect rats against convulsions, and that these 
effects can be selectively blocked by their respective opioid 
antagonists, suggest that both mu and delta opioid receptors 
mediate the anticonvuisant properties of these ligands in the 
flurothyl and MES seizure models. More recently, the re- 
sults of experiments using morphine and DAGO have impli- 
cated mu receptors (but not delta) in the effect of opioids to 
limit kindled amygdaloid seizures (2). 
These data are reinforced by other observations that mu 
and delta opioid receptors are involved in the opioid control 
of seizure protection. For example, the anticonvulsant ef- 
fects of DADLE and etorphine were shown to be antago- 
nized by ICI 154,129 and fl-FNA, respectively (36), while 
other pharmacological studies have demonstrated anticon- 
vulsant effects of synthetic agonist analogs of enkephalin 
which possess mixed mu and delta receptor selectivities (5, 
28, 37). 
The anticonvulsant properties of opioid peptides are of  
significant importance in characterizing the endogenous 
regulation or pharmacological control of seizure activity. 
Initial observations that opioid peptides produced noncon- 
vulsive EEG seizure patterns in rats (12, 35, 40) resulted in 
speculation as to their possible role in the pathophysiology of 
epilepsy. Thus, it was originally suggested that the endoge- 
nous peptides may in fact be epileptogenic (40), not anticon- 
vulsant as the present results suggest. However, with few 
exceptions (see below), the proconvulsant properties of 
opioid peptides appear to be relatively insensitive to opioid 
antagonists, generally requiring doses of naloxone in the 
order of 2-10 mg/kg (or greater) before even partial antago- 
nism can be seen. These observations suggest that the 
proconvulsant actions may be due to nonspecific (high 
dose) effects, possibly involving nonopioid systems (9,28). 
Alternatively, the results of several electrophysiological 
studies indicate that these epileptogenic responses result 
from an effect of  mu opioid peptides to indirectly excite hip- 
pocampal function through disinhibition of inhibitory inter- 
neurons (4, 10, 45). In support of this we (38) and others (19) 
have recently demonstrated that the nonconvulsive EEG 
seizures resulting from the ICV administration of enkephalin 
(38), or generalized convulsions produced by intrahippo- 
campal injections of enkephalin (19), are mediated by spe- 
cific interactions with the mu receptor subtype. Therefore, 
under certain experimental conditions, epileptogenic prop- 
erties can be demonstrated for mu selective opioid peptides. 
It is unlikely however that delta or kappa opioids modulate 
epileptogenic activity since EEG seizures or generalized 
convulsions have not been associated with injections of 
DPDPE and DPLPE (38), dynorphin (1,42), or the selective 
nonpeptide kappa opioid U50,488 (34,41) (F. C. Tortella, un- 
published observation). 
In contrast to the putative proconvulsant actions of opioid 
peptides, their inhibitory anticonvulsant effects in numerous 
species and experimental models clearly represent specific, 
receptor-mediated properties of their general pharmacology 
(28). Additionally, rather than endogenous opioid systems 
activating seizures, studies using behavioral, EEG, receptor 
binding, immunohistochemical and radioimmunoassay 
endpoints have clearly established the converse; i.e., that 
seizures activate endogenous opioid systems (5, 15, 21, 28, 
33). Consequently, it has been proposed that the seizure ac- 
tivation of endogenous opioids may function to "turn-off" or 
self-limit convulsive behaviors (5, 28, 33). The recent iden- 
tification of an opioid peptide-like endogenous anticonvulsant 
substance in rat CSF following a generalized convulsion 
supports this hypothesis (30,31). 
Results of the present study and others (3, l l ,  34, 41) 
demonstrate that opioid peptides with pharmacological 
selectivity for mu, delta, and kappa binding sites are anti- 
convulsant. It is interesting to note that mu, delta and kappa 
opioids selectively hyperpolarize neurons throughout the 
CNS (7, 8, 44) and that endogenous opioids are localized in 
fiber tracts throughout the brain and spinal cord that are 
involved in the generation and spread of seizure activity (16, 
21, 24, 26, 43). Therefore, it seems possible that opioid pep- 
tides may indeed function as endogenous anticonvulsants in 
the CNS, modulating the underlying mechanisms of seizure 
arrest and refractoriness which are critical to the suppression 
of convulsions. 
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